| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
25,710,000 |
| Market
Cap: |
15.07(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,253,345 |
| 52
Week Range: |
$267.56 - $601.03 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 24.7 |
| Insider 3/6 Months : 25.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
165,683 |
165,683 |
302,053 |
| Total Buy Value |
$0 |
$61,921,024 |
$61,921,024 |
$91,986,217 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
3 |
3 |
6 |
| Total Shares Sold |
34,312 |
336,052 |
400,020 |
711,038 |
| Total Sell Value |
$16,782,279 |
$126,244,229 |
$148,133,770 |
$225,287,204 |
| Total People Sold |
4 |
7 |
11 |
12 |
| Total Sell Transactions |
4 |
18 |
34 |
62 |
| End Date |
2025-09-04 |
2025-06-03 |
2024-12-03 |
2023-12-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sibold William John |
President and CEO |
• • – |
2025-12-04 |
4 |
S |
$575.34 |
$1,380,816 |
D/D |
(2,400) |
150,074 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2025-12-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
152,474 |
|
- |
|
| Dier Mardi |
EVP and CFO |
• – – |
2025-12-02 |
4 |
AS |
$570.39 |
$2,413,416 |
D/D |
(4,173) |
10,440 |
|
- |
|
| Dier Mardi |
EVP and CFO |
• – – |
2025-12-02 |
4 |
OE |
$251.63 |
$1,050,052 |
D/D |
4,173 |
14,613 |
|
- |
|
| Huntsman Carole |
Chief Commercial Officer |
• – – |
2025-11-21 |
4 |
AS |
$547.27 |
$1,082,986 |
D/D |
(1,958) |
10,032 |
|
9% |
|
| Levy Richard S |
Director |
– • – |
2025-11-13 |
4 |
AS |
$514.67 |
$4,428,198 |
D/D |
(8,500) |
21,197 |
|
16% |
|
| Levy Richard S |
Director |
– • – |
2025-11-13 |
4 |
OE |
$7.36 |
$117,160 |
D/D |
8,500 |
29,697 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2025-11-05 |
4 |
S |
$480.24 |
$8,027,354 |
D/D |
(16,575) |
2,627 |
|
-22% |
|
| Bate Kenneth |
Director |
– • – |
2025-11-05 |
4 |
OE |
$9.45 |
$3,399,036 |
D/D |
16,575 |
19,202 |
|
- |
|
| Sibold William John |
President and CEO |
• • – |
2025-09-09 |
4 |
S |
$445.63 |
$3,243,741 |
D/D |
(7,279) |
102,474 |
|
-29% |
|
| Sibold William John |
President and CEO |
• • – |
2025-08-21 |
4 |
AS |
$400.03 |
$3,047,756 |
D/D |
(7,616) |
109,753 |
|
47% |
|
| Baker Brothers Life Sciences Lp |
|
– • – |
2025-08-20 |
4 |
B |
$380.44 |
$23,071,366 |
I/I |
59,901 |
1,947,968 |
0.01 |
48% |
|
| Baker Brothers Life Sciences Lp |
|
– • – |
2025-08-18 |
4 |
B |
$353.88 |
$24,979,827 |
I/I |
68,618 |
1,859,091 |
0.01 |
48% |
|
| Baker Brothers Life Sciences Lp |
|
– • – |
2025-08-18 |
4 |
B |
$372.87 |
$13,869,831 |
I/I |
37,164 |
1,893,120 |
0.01 |
48% |
|
| Kelley Shannon T |
General Counsel |
• – – |
2025-08-18 |
4 |
AS |
$358.66 |
$479,627 |
D/D |
(1,304) |
9,173 |
|
53% |
|
| Bate Kenneth |
Director |
– • – |
2025-08-15 |
4 |
S |
$363.41 |
$3,652,009 |
D/D |
(10,000) |
2,627 |
|
-57% |
|
| Bate Kenneth |
Director |
– • – |
2025-08-15 |
4 |
OE |
$16.46 |
$164,600 |
D/D |
10,000 |
12,627 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2025-08-13 |
4 |
AS |
$358.23 |
$47,825,149 |
D/D |
(129,172) |
187,164 |
|
60% |
|
| Friedman Paul A |
Director |
– • – |
2025-08-13 |
4 |
OE |
$9.45 |
$1,220,675 |
D/D |
129,172 |
316,336 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2025-08-12 |
4 |
AS |
$350.87 |
$15,388,279 |
D/D |
(43,263) |
461,044 |
|
66% |
|
| Taub Rebecca |
Director |
– • – |
2025-08-12 |
4 |
OE |
$9.45 |
$408,835 |
D/D |
43,263 |
504,307 |
|
- |
|
| Friedman Paul A |
Director |
– • – |
2025-08-12 |
4 |
AS |
$350.93 |
$15,509,469 |
D/D |
(43,605) |
187,164 |
|
66% |
|
| Friedman Paul A |
Director |
– • – |
2025-08-12 |
4 |
OE |
$9.45 |
$412,067 |
D/D |
43,605 |
230,769 |
|
- |
|
| Taub Rebecca |
Director |
– • – |
2025-08-11 |
4 |
AS |
$350.18 |
$1,120,753 |
D/D |
(3,200) |
461,044 |
|
71% |
|
| Taub Rebecca |
Director |
– • – |
2025-08-11 |
4 |
OE |
$9.45 |
$30,240 |
D/D |
3,200 |
464,244 |
|
- |
|
245 Records found
|
|
Page 1 of 10 |
|
|
6.32 (1.09%) 
